They recommended the measurement of ApoB and ApoA-I in order to assess the atherogenic potential of lipid disorders.19 Here, we observed that bLF can decrease the elevated apoB levels and ApoB/ApoA ratios in HCD rats. The gene discussed is APOA1; the disease is heavy chain disease.